RxDoctor Payments Data

Adel Soliman, MD

Cardiovascular Disease · Rochester, NYNPI 1265433403

Payments from drug & device makers

$3,838in general payments, 2019–2025

Across 141 payments — averaging $27.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Pfizer$366
  • Novartis$350
  • E.r. Squibb & Sons, L.L.C.$239
  • Amgen$186
  • Biotronik Inc.$116
  • plus $598 from 14 others

What the payments were for

  • Travel & lodging$1,48639%
  • Food & beverage$2,21658%
  • Education$1364%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,838 in reported general payments places this provider in the 65th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$434,051
Medicare patients
989
Services billed
6,541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban687$799,620
EntrestoSacubitril/Valsartan325$406,577
JardianceEmpagliflozin195$245,640
FarxigaDapagliflozin Propanediol188$185,258
MultaqDronedarone Hcl125$172,929
Repatha SureclickEvolocumab133$154,794
XareltoRivaroxaban77$96,594
Praluent PenAlirocumab37$26,101
BrilintaTicagrelor16$16,618
Propafenone Hcl ErPropafenone Hcl80$15,093
Metoprolol Succinate481$9,195
DapagliflozinDapagliflozin Propanediol15$7,739
Dofetilide22$7,097
Atorvastatin Calcium430$6,497
Rosuvastatin Calcium320$6,441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$366$799,620687 claims
NovartisEntresto$350$406,577325 claims
Boehringer IngelheimJardiance$58$245,640195 claims
Sanofi-aventis U.S. LLCMultaq$61$172,929125 claims
Johnson & JohnsonXarelto$45$96,59477 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →